FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery.
Barbato MI, Barone AK, Aungst SL, Miller CP, Ananthula S, Bi Y, Yang Y, Li X, Xiong Y, Fan J, Dorff SE, Zhao H, Zhou H, Pradhan S, Scepura B, Sinha AK, Stephenson M, Bhatnagar V, Saber H, Rahman NA, Tang S, Pazdur R, Kluetz PG, Larkins E, Drezner N.
Barbato MI, et al. Among authors: ananthula s.
Clin Cancer Res. 2025 Sep 5:10.1158/1078-0432.CCR-25-1333. doi: 10.1158/1078-0432.CCR-25-1333. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 40911439
Free PMC article.